Acorda Therapeutics, Inc.
ACOR · NASDAQ
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Market Cap | $2,795 | $2,421 | $3,105 | $2,695 |
| - Cash | $9,364 | $30,360 | $32,468 | $25,270 |
| + Debt | $195,920 | $190,897 | $186,089 | $181,495 |
| Enterprise Value | $189,351 | $162,958 | $156,726 | $158,920 |
| Revenue | $20,289 | $37,985 | $27,715 | $29,675 |
| % Growth | -46.6% | 37.1% | -6.6% | – |
| Gross Profit | $16,582 | $24,696 | $24,328 | $26,610 |
| % Margin | 81.7% | 65% | 87.8% | 89.7% |
| EBITDA | -$12,666 | -$230,764 | $372 | $3,236 |
| % Margin | -62.4% | -607.5% | 1.3% | 10.9% |
| Net Income | -$27,395 | -$217,761 | -$8,888 | -$9,381 |
| % Margin | -135% | -573.3% | -32.1% | -31.6% |
| EPS Diluted | -22.06 | -225.81 | -7.16 | -7.55 |
| % Growth | 90.2% | -3,053.8% | 5.2% | – |
| Operating Cash Flow | -$20,185 | -$3,018 | $7,608 | -$11,556 |
| Capital Expenditures | $0 | -$44 | -$220 | $0 |
| Free Cash Flow | -$20,185 | -$3,062 | $7,388 | -$11,556 |